A recent study suggests that patients who come off new weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Published data in a leading health publication shows that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals using these drugs should be aware of the danger of rapid rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight within about 18 months.
Comparing Therapies
The study, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Scientists note that people who shed pounds through lifestyle changes alone typically see a slower weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Experts propose the way of the jabs is key to understanding the amplified weight return.
The injections copy a natural hormone called GLP-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement results in appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Medical guidelines recommend the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts argue that, given the significant potential of relapse, the therapy might need to be life-long.
This opinion is echoed by pharmaceutical companies, who say that the findings "underscore the persistent character of obesity," comparing it to managing diseases like diabetes.
Patient Accounts
People who have stopped the jabs describe a intense resurgence of appetite.
"I experienced something that goes on and you become starving," said an individual.
This challenge is worsened if individuals have not established sustainable dietary or behavioural changes during therapy.
Growing Adoption
Figures indicate that millions of adults in the UK have used these injections in the last 12 months, with desire remaining high.
- Use is higher among females than men.
- The middle-aged age group shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while these medications are potent tools for weight loss, they are not a permanent cure and lasting health benefits likely depends on combined behavioural support.
